Curbstone Financial Management Corp Grows Stake in Johnson & Johnson (NYSE:JNJ)

Curbstone Financial Management Corp boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 26,732 shares of the company’s stock after buying an additional 280 shares during the period. Johnson & Johnson makes up approximately 0.8% of Curbstone Financial Management Corp’s holdings, making the stock its 27th largest holding. Curbstone Financial Management Corp’s holdings in Johnson & Johnson were worth $3,866,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of JNJ. Charter Oak Capital Management LLC lifted its stake in Johnson & Johnson by 15.7% in the fourth quarter. Charter Oak Capital Management LLC now owns 12,930 shares of the company’s stock worth $1,870,000 after purchasing an additional 1,753 shares during the last quarter. Buffington Mohr McNeal lifted its stake in shares of Johnson & Johnson by 10.2% during the 4th quarter. Buffington Mohr McNeal now owns 4,067 shares of the company’s stock worth $588,000 after acquiring an additional 375 shares during the last quarter. Cascade Investment Advisors Inc. grew its position in Johnson & Johnson by 2.4% in the 4th quarter. Cascade Investment Advisors Inc. now owns 10,142 shares of the company’s stock valued at $1,467,000 after acquiring an additional 235 shares during the last quarter. Northwest Financial Advisors increased its stake in Johnson & Johnson by 5.0% in the fourth quarter. Northwest Financial Advisors now owns 9,919 shares of the company’s stock worth $1,435,000 after purchasing an additional 469 shares during the period. Finally, Nilsine Partners LLC lifted its position in shares of Johnson & Johnson by 15.4% during the fourth quarter. Nilsine Partners LLC now owns 20,869 shares of the company’s stock worth $3,018,000 after purchasing an additional 2,787 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Insider Transactions at Johnson & Johnson

In other news, Director Mark A. Weinberger bought 1,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, December 12th. The stock was bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $147,220. The trade was a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on JNJ shares. Citigroup reduced their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Stifel Nicolaus decreased their price target on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research note on Thursday, January 23rd. Guggenheim increased their price objective on Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a report on Thursday, January 23rd. Finally, Wolfe Research began coverage on Johnson & Johnson in a research note on Friday, November 15th. They set an “outperform” rating and a $190.00 price target on the stock. Nine equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $170.44.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $152.09 on Friday. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85. The business’s fifty day simple moving average is $147.67 and its 200-day simple moving average is $156.07. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The company has a market cap of $366.17 billion, a PE ratio of 22.87, a PEG ratio of 2.43 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The company had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same period in the prior year, the company posted $2.29 EPS. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. Analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.26%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.